

Applicant(s) : Guangwen WEI, et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 2

29. (New) A recombinant super-compound interferon with a Seq. ID No.: 1 with higher efficacy than all the interferons described in U.S. Patent Nos. 4,695,623 or 4,897,471.

30. (New) The interferon of claim 29, wherein the interferon is α , β , or ω .

31. (New) A super-compound interferon of claim 29, produced by a high efficiency expression system which uses a special promoter.

32. (New) The super-compound interferon of claim 31, wherein the promoter is P_{BAD} .

33. (New) The super-compound interferon of claim 32, wherein its gene is artificially synthesized cDNA with adjustment of its sequence from the wild-type according to codon preference of *E. coli*.

34. (New) The super-compound interferon of claim 1, which possesses anti-viral or anti-tumor activity.

35. (New) The super-compound interferon of claim 34, which directly inhibits the DNA duplication and secretion of HBsAg and HBeAg of Hepatitis B Virus.

36. (New) A composition comprising the recombinant super-compound interferon of claim 1 and a suitable carrier.

37. (New) A pharmaceutical composition comprising the recombinant super-compound interferon of claim 29 and a pharmaceutically acceptable carrier.